Fiche du document
15 janvier 2020
- handle: 10670/1.8ny5lt
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31961089
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7B31C4DA5F5B2
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Deficiency Shortages Scientific research Science research Science--Research Clinical sciences Medical profession Article Biologic markers Biological markers Biomarkers Markers, BiochemicalCiter ce document
A. Vernadou et al., « Oncologie [Advances in Oncology 2019] », Serveur académique Lausannois, ID : 10670/1.8ny5lt
Métriques
Partage / Export
Résumé
Driven by highly specialized medicine, research and the quest for personalization of treatments, oncology witnessed substantial advances in 2019. This year numerous treatments have consolidated their importance and broadened their indications. Multiple innovative treatments, currently under study, brought hope for future advances, while biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), BRCA1/2 gene mutations, and homologous recombination deficiency (HRD) allowed better selection and customization of available treatments. This article provides an overview of this year's advances in oncology.